<code id='FE359EF197'></code><style id='FE359EF197'></style>
    • <acronym id='FE359EF197'></acronym>
      <center id='FE359EF197'><center id='FE359EF197'><tfoot id='FE359EF197'></tfoot></center><abbr id='FE359EF197'><dir id='FE359EF197'><tfoot id='FE359EF197'></tfoot><noframes id='FE359EF197'>

    • <optgroup id='FE359EF197'><strike id='FE359EF197'><sup id='FE359EF197'></sup></strike><code id='FE359EF197'></code></optgroup>
        1. <b id='FE359EF197'><label id='FE359EF197'><select id='FE359EF197'><dt id='FE359EF197'><span id='FE359EF197'></span></dt></select></label></b><u id='FE359EF197'></u>
          <i id='FE359EF197'><strike id='FE359EF197'><tt id='FE359EF197'><pre id='FE359EF197'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:entertainment    Page View:6
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In